# Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

> **NCT04134260** · PHASE3 · RECRUITING · sponsor: **NRG Oncology** · enrollment: 586 (estimated)

## Conditions studied

- Prostate Adenocarcinoma
- Stage I Prostate Cancer AJCC v8
- Stage II Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Apalutamide
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** Computed Tomography
- **DRUG:** Hormone Therapy
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT04134260
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-04-16
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 586 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04134260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04134260, "Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04134260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*